<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To determine the relevance of MGMT in Barrett's <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, we analyzed promotor hypermethylation and expression of MGMT in Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and its paired precursor lesions from 133 patients using a methylation-specific PCR, real-time RT-PCR and immunohistochemistry </plain></SENT>
<SENT sid="1" pm="."><plain>Hypermethylation was detected in 78.9% of esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, in 100% of Barrett's intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, in 88.9% of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, but only in 21.4% of <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal mucosa samples (P&lt;0.001) and correlated significantly with downregulation of MGMT transcripts (P=0.048) and protein expression (P=0.02) </plain></SENT>
<SENT sid="2" pm="."><plain>Decrease of protein expression was significantly correlated with progressed stage of disease, lymph node invasion and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size </plain></SENT>
<SENT sid="3" pm="."><plain>We conclude, that aberrant promoter methylation of MGMT is a frequent and early event during <z:mp ids='MP_0002006'>tumorigenesis</z:mp> of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>High prevalence of MGMT hypermethylation may represent a candidate marker for improved diagnosis and targeted therapy in Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>